Edwards Lifesciences Corporation (NYSE:EW) is reporting third quarter financial results on Wednesday 21st October 2020, after market close.
According to analysts surveyed by Thomson Reuters, EW is expected to report 3Q20 income of $ 0.44 per share from revenue of $ 1079.78 million.
For the full year, analysts anticipate top line of $ 4382.60 million, while looking forward to income of $ 1.84 per share bottom line.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 1,000.00 million ~ $ 1,200.00 million
Full Year 2020 topline are forecasted in a range of$ 4,000.00 million ~ $ 4,500.00 million, where as bottomline are predicted in a range of $ 1.75 ~ $ 1.95 per share
Click Here For More Historical Outlooks Of Edwards Lifesciences Corporation
Previous Quarter Performance
Edwards Lifesciences Corporation unfold income for the second quarter of $ 0.34 per share, from the revenue of $ 925.00 million. The quarterly earnings dropped 26.09 percent while revenues reduced 14.90 percent compared with the same quarter last year.
The consensus estimates are income of $ 0.17 per share from $ 793.16 million in revenue. The bottom line results beat street analysts by $ 0.17 or 100.00 percent, at the same time, top line results outshined analysts by $ 131.84 million or 16.62 percent.
Stock Performance
Shares of Edwards Lifesciences Corporation traded up $ 0.46 or 0.54 percent on Tuesday, reaching $ 84.46 with volume of 1.16 million shares. Edwards Lifesciences Corporation has traded high as $ 85.65 and has cracked $ 83.69 on the downward trend
The closing price of $ 84.46, representing a 63.08 % increase from the 52 week low of $ 51.51 and a 4.32 % decrease over the 52 week high of $ 87.79.
The company has a market capital of $ 52.51 billion and is part of the Healthcare sector and Medical Devices industry.
Recent Analyst recommendations
- On 14th October 2020, maintained by Piper Sandler at Overweight rating, with $ 93.00 target price.
- On 12th October 2020, maintained by SVB Leerink at Outperform rating, with $ 100.00 target price.
- On 11th September 2020, initiated by Wolfe Research at Underperform rating.
Conference Call
Edwards Lifesciences Corporation will be hosting a conference call at 5:00 PM eastern time on 21st October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.edwards.com
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery.
